Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 141, Issue 4, pp 437–439 | Cite as

Effect of radioprotector indralin on carboplatinum hemotoxicity

  • M. V. Vasin
  • I. B. Ushakov
  • V. Yu. Kovtun
  • S. N. Komarova
  • L. A. Semenova
Article

Abstract

A decrease in carboplatinum hemotoxicity was detected in experiments on C57Bl mice treated with the drug in combination with indralin (urgent radioprotector). Carboplatinum in a dose of 125 mg/kg, injected intraperitoneally, caused 80–100% death; the median term of death was 6 days (3–17). Single oral dose of indralin (100 mg/kg) during the 1st min or 15 min after carboplatinum injection (125 mg/kg) increased animal survival by 40.0–46.7% by day 20 of the experiment primarily during the period of manifest hemotoxicity (days 7–17), indralin injected 1, 2, or 4 h after carboplatinum exhibited no chemoprotective effect.

Key Words

carboplatinum radioprotector indralin toxicity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    M. V. Vasin, I. B. Ushakov, L. A. Semenova, and V. Yu. Kovtun, Radiats. Biol. Radioekol., 41, No. 3, 307–309 (2001).Google Scholar
  2. 2.
    L. A. Il’in, N. M. Rudnyi, N. N. Suvorov, et al., Indralin: Urgent Radioprotector. Antiradiation Effects, Pharmacology, Mechanism of Action, Clinical Picture [in Russian], Moscow (1994).Google Scholar
  3. 3.
    M. K. Pulatova, V. L. Sharygin, and T. G. Shlyakova, Radiats. Biol. Radioekol., 43, No. 1, 29–43 (2003).Google Scholar
  4. 4.
    G. A. Chernov, T. G. Shlyakova, V. L. Sharygin, et al., Izv. Akad. Nauk, ser. Biology, No. 1, 20–37 (1994).Google Scholar
  5. 5.
    C. S. Broome and J. A. Miyan, Ann. NY Acad. Sci., 917, 424–434 (2000).PubMedCrossRefGoogle Scholar
  6. 6.
    G. J. Maestroni, Pharmacol. Res., 32, No. 5, 249–253 (1995).PubMedCrossRefGoogle Scholar
  7. 7.
    G. J. Maestroni, Ann. N.Y. Acad. Sci., 917, 29–37 (2000).PubMedCrossRefGoogle Scholar
  8. 8.
    G. J. Maestroni and A. Conti, Exp. Hematol., 22, No. 3, 313–320 (1994).PubMedGoogle Scholar
  9. 9.
    G. J. Maestroni and A. Conti, Int. J. Immunopharmacol., 16, No. 2, 117–122 (1994).PubMedCrossRefGoogle Scholar
  10. 10.
    G. J. Maestroni, A. Conti, and E. Pedrinis, Blood, 80, 1178–1182 (1992).PubMedGoogle Scholar
  11. 11.
    G. J. Maestroni, M. Togni, and V. Covacci, Exp. Hematol., 25, No. 6, 491–494 (1997).PubMedGoogle Scholar
  12. 12.
    V. Santini, Exp. Opin. Pharmacother., 2, No. 3, 479–489 (2001).CrossRefGoogle Scholar
  13. 13.
    C. Savoye, C. Swenberg, S. Hugot, et al., Int. J. Radiat. Biol., 71, No. 2, 193–202 (1997).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • M. V. Vasin
    • 1
  • I. B. Ushakov
    • 1
  • V. Yu. Kovtun
    • 1
  • S. N. Komarova
    • 1
  • L. A. Semenova
    • 1
  1. 1.State Research and Experimental Institute of Military MedicineMinistry of Defense of the Russian FederationMoscow

Personalised recommendations